How Will Medicare Pay for Non-Sheet Skin Substitutes in 2027?
Non-sheet skin substitutes are wound care products, such as gels, powders, and injectables, that are not supplied as flat sheets. As of November 2026, CMS has finalized national payment for these products in physician offices at $127.14 per square centimeter of wound surface area treated, the same rate as sheet-form products, starting January 1, 2027, replacing the contractor pricing used in 2026.
Office setting:
Non-sheet products and their application codes, G0681 through G0684, get national payment rates under the 2027 Physician Fee Schedule.
Hospital outpatient setting:
Non-sheet products stay packaged, but primary application codes G0681 and G0683 become separately payable.
Sheet-form products:
The $127.14 per square centimeter rate for sheet-form skin substitutes stays the same for 2027.
What CMS Finalized on November 4
On November 4, 2026, CMS released two final rules that together set skin substitute payment for 2027: the CY 2027 Physician Fee Schedule final rule, CMS-1848-F, and the CY 2027 Hospital Outpatient Prospective Payment System final rule, CMS-1850-F. Both build on the CY 2026 policy that began paying most skin substitutes as incident-to supplies at a flat national rate.
Physician Fee Schedule. In 2026, CMS left non-sheet form skin substitutes to contractor pricing, meaning each Medicare Administrative Contractor (MAC) set its own payment. For 2027, CMS finalized national pricing for non-sheet products on a per square centimeter basis, consistent with the $127.14 rate for sheet-form products. CMS explained that for non-sheet products, square centimeters reflect the wound surface area treated, not the physical size or quantity of the product. CMS also said it will establish national payment for the non-sheet application codes G0681 through G0684, similar to how CPT codes 15271 through 15278 are paid.
Hospital outpatient payment. CMS kept the $127.14 per square centimeter rate for sheet-form products, saying it is premature to change the rate before 2026 claims data reflects the new policy. CMS changed its proposal for non-sheet application codes and will pay G0681 and G0683 separately, under status indicator T in APC 5053 and APC 5054. The add-on codes G0682 and G0684 stay packaged, and the non-sheet products themselves remain packaged in the hospital outpatient setting.
Products licensed as biologics under section 351 of the Public Health Service Act continue to be paid under the average sales price methodology. CMS lists the non-sheet products covered by the policy on its skin substitutes page.
Which Podiatry Practices Does This Affect?
The change affects podiatry practices that apply skin substitutes to diabetic foot ulcers and other chronic wounds, especially practices that use gel, powder, liquid, or injectable products. Office-based practices gain predictable national pricing, while podiatrists who treat patients in hospital outpatient wound centers face a different payment setup for the same products.
One question we hear constantly from podiatry practice managers is why the same product pays differently depending on where it is applied. The 2027 rules make that difference sharper. In the office, both the product and its application have national rates. In a hospital outpatient department, the facility is paid for the application but not separately for the non-sheet product.
- Office-based wound care practices. These practices move from MAC-by-MAC contractor pricing to a national rate for non-sheet products, which makes budgeting easier but may lower payment for practices whose MACs paid more.
- Podiatrists working in hospital wound centers. The professional application is billed by the podiatrist, while the facility bills under OPPS, so coordination between the two claims matters.
- Practices treating diabetic foot ulcers. Most skin substitute use in podiatry is tied to diabetic foot ulcers. Accurate diagnosis coding with the E11.6x diabetic foot complication codes supports medical necessity for every application.
- Practices that only use sheet-form grafts. Payment stays at $127.14 per square centimeter, but the overall fee schedule changes for 2027 still apply, including the lower conversion factor for application and evaluation services.
- Multi-location groups. Practices with offices in more than one MAC jurisdiction lose the payment differences they saw under contractor pricing, which simplifies billing but changes margins by location.
Why CMS Standardized Non-Sheet Payment
CMS’s skin substitute reform started in 2026 as a response to rapidly rising spending, which CMS tied to fraud, waste, and abuse in the product market. Paying most products at a flat $127.14 per square centimeter, regardless of brand, removed the incentive to choose the highest-priced product. Non-sheet products were left out because their units, such as milliliters, milligrams, or cubic centimeters, were hard to standardize.
That gap created a problem. If sheet-form products had a fixed national rate and non-sheet products were contractor priced, practices and manufacturers had a reason to shift toward whichever form paid more in a given MAC jurisdiction. In the final rule, CMS said that after further analysis it believes the resource costs per square centimeter for non-sheet products are consistent with sheet-form products, so a single approach makes sense.
Commenters pushed back. Many argued the $127.14 rate is too low, objected to using hospital outpatient data to set it, and asked for an inflation-based update instead of updates based on average sales price. CMS noted it did not propose changes to the rate or how it is calculated, and kept both.
The signal for podiatry practices is that CMS is closing payment gaps between product forms and settings, one rule at a time. Practices that built margins around higher-paying product types or contractor pricing should expect less room in 2027. CMS also said it will keep analyzing claims data and may revisit the rate once 2026 claims reflect the new policy.
Other 2027 payment changes affecting podiatry are covered in our post on podiatry reimbursement under the 2027 Medicare fee schedule.
What Does the New Rate Mean for a Typical Application?
In the physician office, a non-sheet skin substitute applied to a diabetic foot ulcer will be paid at $127.14 per square centimeter of wound surface area treated in 2027, plus a separate national payment for the application code. A 16 square centimeter wound would generate about $2,034 in product payment per application, before geographic adjustment and patient coinsurance.
| Item | 2026 payment approach | 2027 final payment approach |
|---|---|---|
| Sheet-form products, office and hospital outpatient | $127.14 per sq cm | $127.14 per sq cm (unchanged) |
| Non-sheet products, physician office | Contractor priced by each MAC | $127.14 per sq cm of wound surface area |
| Non-sheet application codes G0681 to G0684, physician office | New codes effective April 1, 2026 | National payment, similar to CPT 15271 to 15278 |
| Non-sheet products, hospital outpatient | Packaged | Packaged (unchanged) |
| G0681 and G0683, hospital outpatient | Packaged (status indicator N) | Separately paid (status indicator T, APC 5053 and 5054) |
| Section 351 biologic products | Average sales price methodology | Average sales price methodology (unchanged) |
Here is a simple illustration. Suppose an office-based podiatry practice treats a patient with a 16 square centimeter diabetic foot ulcer using a non-sheet product and applies it four times during a covered course of treatment. At $127.14 per square centimeter, product payment is about $2,034 per application, or about $8,137 across four applications, before the application code payment, geographic adjustment, and coinsurance. These figures are hypothetical, and the number of covered applications depends on your MAC’s local coverage determination.
The key billing detail is that units for non-sheet products are based on the wound area treated, not the amount of product in the package. Measuring and documenting wound size at every application is now directly tied to payment.
What Should Podiatry Practices Do Before January 1, 2027?
Podiatry practices should update their fee schedules, wound measurement documentation, and product purchasing decisions before January claims. These steps cover the work:
- List every non-sheet product you use. Check each one against the CMS skin substitutes product list and confirm its HCPCS code.
- Document wound surface area every time. Record length and width in square centimeters at each application, since payment is based on area treated.
- Use the right application codes. Bill G0681 through G0684 only for non-sheet products and CPT 15271 through 15278 for sheet-form products.
- Compare acquisition cost to $127.14. Make sure each product you stock costs less than the national rate per square centimeter treated.
- Review your MAC’s coverage rules. Confirm which products, how many applications, and what documentation your local coverage determination requires.
- Coordinate with hospital wound centers. Align documentation with facilities where non-sheet products remain packaged in 2027.
- Update 2027 fee schedules and claim edits. Load the new national rates so expected payments match January remittances.
Providers often come to us after skin substitute claims start denying for wound measurement or coverage gaps, usually after months of unpaid applications. Billing companies in our network that specialize in podiatry wound care track these documentation rules closely, and the conservative sharp debridement documented with codes in our CPT 97597 debridement billing guide often precedes a skin substitute application.
Applying skin substitutes and not sure your 2027 claims will pay correctly? Get matched with podiatry billing companies that know wound care billing, free, usually within 30 minutes.
Common Mistakes With Skin Substitute Billing
The most common issue we see providers run into is billing product units based on what was opened instead of what was applied to the wound. With non-sheet products now paid per square centimeter of wound area, that mistake becomes a direct payment and audit risk.
- Mixing up application codes. Using CPT 15271 through 15278 for a non-sheet product, or G0681 through G0684 for a sheet product, invites denials.
- Skipping wound measurements. Without documented length and width at each application, the billed square centimeters cannot be supported.
- Assuming hospital and office rules match. In 2027, non-sheet products are separately paid in the office but packaged in the hospital outpatient setting.
- Ignoring coverage limits. National pricing does not change coverage. MAC local coverage determinations still control which products are covered, how many applications are allowed, and what conservative care must come first.
- Overlooking vascular status. Many MAC coverage policies consider circulation before skin substitutes are applied. Our CPT 93922 ABI billing guide covers the vascular testing that often supports wound care decisions.
- Stocking products above the rate. A product that costs more than $127.14 per square centimeter treated loses money on every application.
- Carrying 2026 contractor rates forward. Practices that loaded MAC-specific non-sheet prices into their systems in 2026 need to replace them with the national rate, or January payment variance reports will be wrong from day one.
Wound care errors are a growing share of rejected claims, which we covered in our post on rising podiatry claim denials in 2026.
In-House Billing vs. a Podiatry Billing Partner
Many podiatry practices handle wound care billing internally, and for practices that apply skin substitutes only occasionally, that can work. The challenge is that skin substitute billing now involves product-specific HCPCS codes, two families of application codes, wound measurement documentation, MAC coverage rules, and different payment rules by setting.
Practices that run active wound care programs, often across several offices and a hospital wound center, see the stakes quickly. A single application can involve thousands of dollars in product payment, and a missing measurement or wrong application code can put the entire claim at risk. CMS has repeatedly tied its skin substitute reforms to fraud, waste, and abuse, which makes documentation gaps more costly when claims are reviewed.
Podiatry Bill Co, part of Billing Service Quotes, matches podiatry practices with billing companies in our network that handle podiatry and wound care billing. We have matched more than 2,000 providers across all 50 states, the service is free to providers, and most practices are connected within 30 minutes. Our process includes a human review of each request, so a wound care practice is matched with billing companies that understand skin substitute coding, MAC coverage rules, and the documentation auditors look for.
Billing companies in our network offer credentialing, contracting, compliance, and full revenue cycle support, and many are software agnostic. Rates start as low as 2.95%. For related coverage changes, see our post on the topical oxygen therapy Medicare LCD, and for a code refresher, use our podiatry billing and coding cheat sheet.
Frequently Asked Questions
A non-sheet skin substitute is a wound care product supplied in a form other than a flat sheet, such as a gel, powder, liquid, injectable, or 3D-printed construct. Because these products are measured in units like milliliters or milligrams, CMS paid them through contractor pricing in 2026 before finalizing national pricing for 2027.
In the physician office, Medicare will pay $127.14 per square centimeter of wound surface area treated, the same as sheet-form products, starting January 1, 2027. Payment is geographically adjusted and subject to patient coinsurance. In hospital outpatient departments, non-sheet products remain packaged into other payments.
Use HCPCS codes G0681 through G0684 only for applying non-sheet form skin substitutes. G0681 and G0682 cover wounds up to 100 square centimeters, and G0683 and G0684 cover wounds of 100 square centimeters or more. Sheet-form products use CPT codes 15271 through 15278.
No. CMS kept the $127.14 per square centimeter rate for sheet-form skin substitutes in both the physician office and hospital outpatient settings for 2027. CMS said it is premature to change the rate before 2026 claims data reflects the new policy, and it may revisit the rate in future rulemaking.
Not exactly. In 2027, hospital outpatient departments receive separate payment for non-sheet application codes G0681 and G0683, but the non-sheet products themselves stay packaged. Sheet-form products are paid at $127.14 per square centimeter in both hospital outpatient and office settings.
No. National pricing sets how much Medicare pays, not whether a product is covered. Your MAC’s local coverage determination still governs covered products, the number of allowed applications, required conservative care, and documentation. Practices should check coverage before applying any product.
Next Steps
- Tracking 2027 payment changes? Read about podiatry reimbursement under the 2027 Medicare fee schedule.
- Reporting wound care quality? See the 2026 MIPS podiatry value pathway.
- Need billing rules in one place? Review our podiatry billing guidelines.
- Ready for help? Explore Podiatry Bill Co and get matched with a billing partner.